PL4122447T3 - Preparat białka fuzyjnego zawierający białka il-2 i cd80 - Google Patents

Preparat białka fuzyjnego zawierający białka il-2 i cd80

Info

Publication number
PL4122447T3
PL4122447T3 PL21770734.8T PL21770734T PL4122447T3 PL 4122447 T3 PL4122447 T3 PL 4122447T3 PL 21770734 T PL21770734 T PL 21770734T PL 4122447 T3 PL4122447 T3 PL 4122447T3
Authority
PL
Poland
Prior art keywords
proteins
fusion protein
protein preparation
preparation
fusion
Prior art date
Application number
PL21770734.8T
Other languages
English (en)
Inventor
Myung Ho Jang
Young Min Oh
Heonchang LIM
Original Assignee
Gi Innovation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation, Inc. filed Critical Gi Innovation, Inc.
Publication of PL4122447T3 publication Critical patent/PL4122447T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL21770734.8T 2020-03-18 2021-03-17 Preparat białka fuzyjnego zawierający białka il-2 i cd80 PL4122447T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200033231 2020-03-18
PCT/KR2021/003312 WO2021187897A1 (ko) 2020-03-18 2021-03-17 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제

Publications (1)

Publication Number Publication Date
PL4122447T3 true PL4122447T3 (pl) 2025-11-24

Family

ID=77771825

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21770734.8T PL4122447T3 (pl) 2020-03-18 2021-03-17 Preparat białka fuzyjnego zawierający białka il-2 i cd80

Country Status (9)

Country Link
US (1) US12642764B2 (pl)
EP (1) EP4122447B1 (pl)
JP (1) JP7697959B2 (pl)
KR (2) KR102604984B1 (pl)
CN (1) CN115666522B (pl)
ES (1) ES3040184T3 (pl)
PL (1) PL4122447T3 (pl)
TW (1) TWI825397B (pl)
WO (1) WO2021187897A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025521387A (ja) * 2022-06-22 2025-07-10 ジーアイ・イノベイション・インコーポレイテッド 抗－ｃｄ７３抗体およびｉｌ－２を含む融合タンパク質およびその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
ATE525062T1 (de) 2007-12-28 2011-10-15 Baxter Int Gegendruckfiltration von proteinen
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR102386735B1 (ko) * 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
SG11202005873QA (en) 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof

Also Published As

Publication number Publication date
WO2021187897A1 (ko) 2021-09-23
CN115666522B (zh) 2025-05-27
EP4122447C0 (en) 2025-08-13
EP4122447B1 (en) 2025-08-13
US12642764B2 (en) 2026-06-02
TW202200193A (zh) 2022-01-01
KR20230160763A (ko) 2023-11-24
TWI825397B (zh) 2023-12-11
KR102923786B1 (ko) 2026-02-09
JP7697959B2 (ja) 2025-06-24
JP2023517511A (ja) 2023-04-26
CN115666522A (zh) 2023-01-31
EP4122447A1 (en) 2023-01-25
US20230125871A1 (en) 2023-04-27
EP4122447A4 (en) 2023-11-01
KR102604984B1 (ko) 2023-11-23
KR20210117200A (ko) 2021-09-28
ES3040184T3 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
AU2021365129A9 (en) Interleukin-2-fc fusion proteins and methods of use
PL4232463T3 (pl) Białka fuzyjne interleukiny-2-fc i sposoby ich stosowania
IL288373A (en) flt3l-fc fusion proteins and methods of use
IL275592B (en) A fusion protein containing the il-2 protein and the cd80 protein and its uses
EP3936526A4 (en) BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
EP4194556A4 (en) FUSION PROTEIN AND USE THEREOF
EP3868403A4 (en) TACI-FC FUSION PROTEIN AND USE THEREOF
EP4176893A4 (en) DESIGN AND APPLICATION OF A FUSION PROTEIN VACCINE PLATFORM
IL293364B2 (en) Pharmaceutical preparation for the treatment of cancer containing fusion proteins containing IL-2 protein and 80CD protein and immune checkpoint inhibitors
EP3998282A4 (en) NEW FUSION PROTEIN AND ITS USE
EP4186517A4 (en) FUSION PROTEIN COMPRISING PD-L1 PROTEIN AND USE THEREOF
EP4274892A4 (en) SIALIDASE-HER2 ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
EP4174088A4 (en) FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF
EP3994180A4 (en) ANTIBODY-HER2-SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
IL304228A (en) Sialidase-antibody-pd-1 fusion proteins and methods of using them
IL313553A (en) Fusion proteins containing alpha-L-iduronidase enzymes and methods
EP4122447A4 (en) FUSION PROTEIN PREPARATION WITH IL-2 AND CD80 PROTEINS
IL307256A (en) Immunogenic fusion proteins
EP4509136A4 (en) FUSION PROTEIN AND ITS USE
EP4423260A4 (en) Truncated and fusion proteins
EP4107190A4 (en) FUSION PROTEINS AND USES THEREOF
EP4162945A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVEMENT OF RADIATION THERAPY WITH FUSION PROTEIN WITH IL-2 PROTEIN AND CD80 PROTEIN
HK40109162A (en) Il-2 variants and fusion proteins thereof
CA3307159A1 (en) Anti-pd1-il10 fusion protein and use thereof
AU2021903439A0 (en) Truncated and fusion proteins